BC Week In Review | Sep 14, 2015
Company News

Aeterna Zentaris deal

Aeterna Zentaris granted an undisclosed, privately held German life sciences company a 12-month option to license exclusive, worldwide rights to develop and commercialize Aeterna’s live, recombinant, oral, allogeneic tumor vaccine technology, including AEZS-120 . Preclinical drug...
BC Week In Review | Oct 8, 2012
Clinical News

Aeterna Zentaris preclinical data

In mice, single and multiple doses of oral AEZS-120 each led to significant and comparable protection from challenge with a recombinant prostate-specific antigen ( KLK3 ; PSA) expressing tumor cell line. Aeterna Zentaris said that the...
Items per page:
1 - 2 of 2